Glaucoma News

Once-daily dosing of NCX 470 demonstrated noninferiority compared with latanoprost in lowering IOP in patients with open-angle glaucoma or ocular hypertension in the phase 3 Mont Blanc clinical trial.

SAN DIEGO — Visual field defect on baseline 10-2 testing most effectively predicted subsequent progression on 24-2 testing in patients with glaucoma, Michael J. Sullivan-Mee, OD, FAAO, said at an Academy 2022 press conference.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Ye Elaine Wang, MD, discusses MicroPulse transscleral laser therapy from Iridex.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Michelle Senchyna, PhD, of Aerie Pharmaceuticals, provides an update on the company’s ongoing projects.

We are fortunate to have many options for the treatment of glaucoma, including several classes of glaucoma medications, selective laser trabeculoplasty and minimally invasive glaucoma surgery.

CHICAGO — In this Healio Video Perspective from the AAO meeting, I. Paul Singh, MD, shares data about the Glaukos iStent infinite, designed to reduce IOP.

In this exclusive surgical video for Healio/OSN, I. Paul Singh, MD, uses the iStent inject and the iAccess microgoniotomy device to demonstrate a technique for combining stenting and goniotomy for patients with glaucoma.

CHICAGO — Once-daily sepetaprost was noninferior to twice-daily timolol in reducing IOP in patients with primary open-angle glaucoma or ocular hypertension, according to a study presented at the American Academy of Ophthalmology meeting.

TC-002, a latanoprost ophthalmic solution, met all primary and secondary endpoints in the phase 3 CLEAR pivotal trial, according to a press release from TearClear.

As a specialty, glaucoma has had no shortage of innovation in recent years.